Medtronic has announced that it has stopped the sale of one of its heart pumps due to safety concerns.
According to the company, the decision comes after clinical comparisons showed that the firm's HVAD device, which helps patients with advanced heart failure pump blood, is leading to more strokes and other issues than alternative models.
Specifically, the company confirmed that the HVAD System may experience a delay to restart or a failure to restart after it has stopped. This can be detrimental to the patient's heart condition and could even result in hospitalisation if not addressed.
The Dublin-based business said in a statement: "The company notified physicians to cease new implants of the HVAD system and transition to an alternative means of durable mechanical circulatory support."
"Medtronic is working closely with other stakeholders including Abbott, and with regulatory bodies globally, to help ensure that alternative treatment options are available."
Medtronic acquired the HVAD System in 2016 as part of a $1.1 billion deal to purchase heart pump manufacturer HeartWave International Inc. The device is currently implanted in around 4,000 patients but Medtronic is working within an independent panel of clinician advisors to develop a program to have the device replaced.